Apply For FDI

INQUIRY

Fraud Warning Disclaimer : FDI India warns you against certain individuals that might falsely present themselves as our affiliate agents, representatives, or employees. Under this false pretence, they might try to gain access to your personal information or to acquire money as Consultation fee or any other form or other valuables from you by offering fictitious employment opportunities or by claiming that they are contacting you on our behalf. Don’t fall prey into the fraudulent misrepresentation. Such fraudulent claims and offers are received generally via email, text message, phone, or internet, etc.

FDI India would like to bring to your notice that our authorized official Email ID is inquiry@fdi.finance, . FDI India shall not be liable for any claims, damage, or loss of any kind inflicted by any other unauthorized entity. Be very mindful of such scams.

Legal : We own all the information, images, text, logo, and other content provided by us. The use of information is strictly prohibited without our consent. We hold the right to take a legal action against any individual or organization violating or using our site information.

PHARMACEUTICALS

FDI in Pharmaceuticals in India

India enjoys an important position in the global pharmaceuticals sector with a 20% share of generic medicines in supplies by volume. In addition, the Indian pharmaceutical sector industry supplies 62% percent of global demand for various vaccines, 40% of the generic market in the US, and 25% of all medicine in the UK.

India is the source of 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different Active Pharmaceutical Ingredients (APIs). The export of generic drugs is one of India's core strengths. The country's pharmaceutical exports stood at $24.44 billion in FY 20-21.

The industry has granted incentives totaling INR 21,940 Crore ($ $3 Mn).

100% Foreign Direct Investment (FDI) in pharmaceuticals in India is allowed under the automatic route for green-field pharma.

100% FDI in Drugs and Pharmaceuticals in India is allowed in brownfield pharma, wherein 74% FDI in the Pharmaceuticals Sector is permitted under the automatic route and after that through government approval.

20 %

Generics medicines exports share (global)
24.6 Bn (USD)

Exports worth (FY 21-22)
1.410 Bn (USD)

FDI (April 2021 - March 2022)

1

Largest vaccine producer in the world.
2

Largest manufacturers and exporters of generic medicines.
3

Indian Pharma Industry generates over $11 bn of trade surplus every year.

The pharmaceutical industry is currently valued at $41.7 bn and is expected to reach $65bn by 2024 and $120 bn by 2030.
India's pharmaceuticals exports stood at $24.44 bn in FY 20-21.
The Pharmaceutical industry in India accounts for about 2.4% of the global pharmaceutical industry in value terms.
Generic drugs with a 70% market share form the largest segment of the Pharmaceutical industry in India.
In the domestic market by revenue, Anti-Infectives (13.6%), Cardiac (12.4%), and Gastrointestinal (11.5%) had the most significant market share.

Innovation and R&D
To develop new complex generic drugs
Medical tourism
Quality services at marginal costs compared to US, Europe, and South Asia
Infrastructure development
6 pharma and 2 medical devices parks in the pipeline
New IPR policy
Increased control over patent infringement
Strong drug manufacturing
Expertise in low cost generic patented drugs

June 2021- PharmEasy has received $300 million from its existing investors after acquiring diagnostic firm Thyrocare.
May 2021- Approvals granted under the Production Linked Incentive (PLI) Scheme to Encourage Domestic Manufacturing of Critical Key Starting Materials (KSM), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs).
April 2021- PPL has agreed to purchase a 100 percent stake in Hemmo Pharmaceuticals (Hemmo) for Rs 775 crore in cash and earn-outs based on completing certain milestones.
March 2021- The National Pharmaceutical Pricing Authority (NPPA) set the pricing of 81 pharmaceuticals, including off-patent anti-diabetic treatments, allowing patients to reap the benefits of patent expiration.
February 2021- To strengthen the state's biopharma business, the Telangana government teamed with Cytiva to create a "Fast Trak" facility.
December 2020- The Coalition for Epidemic Preparedness Innovations (CEPI), a global collaboration to create vaccines, has partnered with Biological E, an Indian vaccine manufacturer, to help it progress its Covid-19 subunit vaccine candidate.
November 2020- Hetero Labs, situated in Hyderabad, will collaborate with the Russian Direct Investment Fund (RDIF) to produce 100 million Sputnik V vaccine doses per year.

3,039 crore FDI inflow in pharmaceuticals from April 2020 to September 2020.
100 percent FDI in pharma sector allowed in green-field pharma
74% FDI in the pharmaceuticals sector is allowed for brownfield pharmaceuticals projects